Pharmacologic predictors of benzodiazepine response trajectory in anxiety disorders: a Bayesian hierarchical modeling meta-analysis
- 1 October 2021
- journal article
- research article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 28 (1), 53-60
- https://doi.org/10.1017/s1092852921000870
Abstract
Background Despite frequent benzodiazepine use in anxiety disorders, the trajectory and magnitude of benzodiazepine response and the effects of benzodiazepine potency, lipophilicity, and dose on improvement are unknown. Methods We performed a meta-analysis using weekly symptom severity data from randomized, parallel group, placebo-controlled trials of benzodiazepines in adults with anxiety disorders. Response was modeled for the standardized change in continuous measures of anxiety using a Bayesian hierarchical model. Change in anxiety was evaluated as a function of medication, disorder, time, potency, lipophilicity, and standardized dose and compared among benzodiazepines. Results Data from 65 trials (73 arms, 7 medications, 7110 patients) were included. In the logarithmic model of response, treatment effects emerged within 1 week of beginning treatment (standardized benzodiazepine-placebo difference = -0.235 +/- 0.024, CrI: -0.283 to -0.186, P < .001) and placebo response plateaued at week 4. Doses <6 mg per day (lorazepam equivalents) produced faster and larger improvement than higher doses (P = .039 for low vs medium dose and P = .005 for high vs medium dose) and less lipophilic benzodiazepines (beta = 0.028 +/- 0.013, P = .030) produced a greater response over time. Relative to the reference benzodiazepine (lorazepam), clonazepam (beta = -0.217 +/- 0.95, P = .021) had a greater trajectory/magnitude of response (other specific benzodiazepines did not statistically differ from lorazepam). Conclusions In adults with anxiety disorders, benzodiazepine-related improvement emerges early, and the trajectory and magnitude of improvement is related to dose and lipophilicity. Lower doses and less lipophilic benzodiazepines produce greater improvement.Keywords
This publication has 31 references indexed in Scilit:
- EFFICACY AND TOLERABILITY OF ANTIDEPRESSANTS IN PEDIATRIC ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSISDepression and Anxiety, 2014
- A Double-Blind Randomized Controlled Trial of Augmentation and Switch Strategies for Refractory Social Anxiety DisorderAmerican Journal of Psychiatry, 2014
- Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trialsJournal of Psychopharmacology, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Modulation of 5HT1A receptors in the hippocampus and the raphe area of rats treated with clonazepamProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1993
- Clinical Pharmacokinetics of AlprazolamClinical Pharmacokinetics, 1993
- A comparison of model selection criteriaEconometric Reviews, 1992
- Benzodiazepines in the treatment of sleep disorders: pharmacokinetic aspectsActa Psychiatrica Scandinavica, 1986
- Pharmacokinetics and Clinical Effects of Alprazolam Following Single and Multiple Oral Doses in Patients With Panic DisorderThe Journal of Clinical Pharmacology, 1986
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959